Janux Therapeutics, Inc. SEC filings JANX
Janux Therapeutics, Inc. has 442 filings in SEC EDGAR's recent list, going back to Jul 14, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jun 23, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 28, 2026 | Apr 28, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 22, 2026 | Jan 21, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 19, 2025 | Sep 18, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Other events
|
Dec 5, 2024 | Dec 4, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 2, 2024 | Dec 2, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 22, 2024 | Jul 19, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 28, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 7, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2024 | Mar 8, 2024 |
| 8-K |
Current report
Other events
|
Feb 29, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Other events
|
Feb 28, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Other events
|
Feb 27, 2024 | Feb 27, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 26, 2024 | Feb 26, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 18, 2023 | Jul 17, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jul 17, 2023 | Jul 17, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2023 | Jun 21, 2023 |
| 8-K |
Current report
Listing notice, Shareholder vote results
|
Jun 20, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Material agreement
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 31, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 22, 2022 | Sep 21, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2022 | Jun 14, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Other events
|
May 2, 2022 | May 2, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2022 | Mar 18, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 1, 2021 | Oct 1, 2021 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2021 | Sep 7, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Aug 27, 2021 | Aug 25, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2021 | Aug 10, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 16, 2021 | Jul 15, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jun 15, 2021 | Jun 15, 2021 |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JANX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1817713
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.